Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia
- PMID: 14693762
- PMCID: PMC1771954
- DOI: 10.1136/bjo.88.1.17
Mitomycin C as an adjunct in the treatment of localised ocular surface squamous neoplasia
Abstract
Aim: To report the outcome of topical mitomycin C (MMC) used as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN).
Method: Prospective, non-comparative interventional case series of 27 primary OSSN lesions from 26 patients treated in a single ocular oncology centre over a 4 year period.
Result: 27 cases of OSSN received a treatment regimen of surgical excision, followed by topical MMC. Mean follow up of 27 (SD 12) months (range 12-50, median 25 months) revealed zero recurrences.
Conclusion: MMC treatment following surgical excision decreases the recurrence rate of primary ocular surface neoplasia and should be considered as adjunctive therapy in primary treatment.
References
-
- Lee GA, Hirst LW. Incidence of ocular surface dysplasia in metropolitan Brisbane. Arch Ophthalmol 1992;110:525–7. - PubMed
-
- Lee GA, Hirst LW. Ocular surface squamous neoplasia. Surv Ophthalmol 1995;39:429–50. - PubMed
-
- Majmudar PA, Epstein RJ. Antimetabolites in ocular surface neoplasia. Curr Opin Ophthalmol 1998;9:35–9. - PubMed
-
- Daniell M, Maini R, Tole D. Use of mitomycin C in the treatment of corneal conjunctival intraepithelial neoplasia. Clin Exp Ophthalmol 2002;30:94–8. - PubMed
-
- Khokhar S, Soni A, SinghSethi H, et al. Combined surgery, cryotherapy, and mitomycin-C for recurrent ocular surface squamous neoplasia. Cornea 2002;21:189–91. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical